.png)
Podcast with MedAsian
China healthcare policy landscape
Podcast with MedAsian
Latest Episodes
Section 1260H decoded: How Chinese biotech builds trust in the U.S.
Section 1260H & WuXi AppTec1260H is a policy signaling tool, not a sanction – identifies companies linked to China's military-civil fusionCreates indirect but real consequences: investor scrutiny, partner...
.png)
Beyond the Deal: How Chinese Healthcare Companies Can Build Long-Term Success in the U.S.
Evolution of globalization: Chinese healthcare companies have moved from transactional exports and licensing to becoming globally integrated players—pursuing co-development, overseas manufacturing, acquisitions, and ecosystem partnerships....
Views on the Trump visit to Beijing and outlook on US-China Bilateral relationship
The Trump visit tested the political will to stabilize U.S.-China relations and prevent uncontrolled escalation amid deep strategic competition, supply chain restructuring, and technology restrictions.Rather than a full reset, it signal...
Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part II)
National strategy: China has elevated AI healthcare into a broader national agenda, linking it to economic modernization, tech leadership, and solving structural pressures like an aging population and uneven medical access.Multi-a...
Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part I)
Surge drivers: Advances in deep learning and large language models, mounting pressure from aging populations and rising costs, plus heavy investment and government backing are converging to make AI a practical, system-shaping force in heal...